ReviewIndian journal of psychological medicine2013
Metabolic syndrome in schizophrenia.
Review in Indian journal of psychological medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.
- Cholesterol and triglyceride levels in first-episode psychosis: systematic review and meta-analysis.The British journal of psychiatry : the journal of mental science · 2017Pooled it
- Trial
- Clostridium butyricum CGMCC 0313.1 improves clinical outcomes of metabolic syndrome in schizophrenic patients.American journal of translational research · 2025Article
- Causal relationship between genetically predicted mental disorders and frailty: a bidirectional and multivariable mendelian randomization study.BMC psychiatry · 2024Article
- Late-stage borreliosis and substance abuse.Heliyon · 2024Article
- Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study andFrontiers in medicine · 2023Article
- Automatic Thoughts, Self-Stigma, and Resilience Among Schizophrenia Patients with Metabolic Syndrome: A Cross-Sectional Study.Neuropsychiatric disease and treatment · 2023Article
- New Paradigms of Old Psychedelics in Schizophrenia.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Metabolic derangements with olanzapine and risperidone in schizophrenia spectrum and other psychotic disorders: A 24-week prospective study.Journal of family medicine and primary care · 2022Article
- Schizophrenia Outside the Brain.Advances in experimental medicine and biology · 2022Article
- Metabolic and clinical effect of alpha-lipoic acid administration in schizophrenic subjects stabilized with atypical antipsychotics: A 12-week, open-label, uncontrolled study.Current research in pharmacology and drug discovery · 2022Article
- Metabolic Syndrome and Dietary Habits in Hospitalized Patients with Schizophrenia: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2021Article
- Genetic Polymorphisms ofJournal of personalized medicine · 2021Article
- A Review of Switching Strategies for Patients with Schizophrenia Comorbid with Metabolic Syndrome or Metabolic Abnormalities.Neuropsychiatric disease and treatment · 2021Review
- COVID-19 and Severe Mental Illness: Impact on patients and its relation with their awareness about COVID-19.Psychiatry research · 2020Article
- A follow-up study of metabolic syndrome in schizophrenia.European archives of psychiatry and clinical neuroscience · 2020Article
- Retinal correlates of psychiatric disorders.Therapeutic advances in chronic disease · 2020Review
- Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of Metabolic Syndrome on Cognitive Remediation's Outcome.Frontiers in psychiatry · 2018Article
- Methylenetetrahydrofo late reductase C677T polymorphism and schizophrenia: Effect of molecular change.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2018Article
- The Wnt Signaling Pathway Effector TCF7L2 Mediates Olanzapine-Induced Weight Gain and Insulin Resistance.Frontiers in pharmacology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To review the data with respect to prevalence of metabolic syndrome (MetS) and its correlates in schizophrenia. For this review, electronic search engines PUBMED, Sciencedirect, and Google Scholar were used. Available data suggests that most of the studies have been of cross-sectional design. Prevalence rates of MetS have varied from 11% to 69% in medicated patients, and 4-26% in drug naive patients in cross-sectional evaluations. Longitudinal studies have shown the prevalence rates to range from 0% to 14% at the baseline in drug naive patients, which increase to as high as 52.4% by 3 months of antipsychotic medication treatment. The prevalence rates of MetS in patients with schizophrenia are much higher than that seen in general population or healthy controls. Though there is no causal association with any demographic or clinical variables, the risk increases with increase in age. Among antipsychotics, there seems to be an association between MetS and atypical antipsychotics like clozapine and olanzapine. Therefore, the psychiatrists should be more vigilant regarding the presence of MetS in these high risk groups. Research on biological correlates of MetS in schizophrenia is still in its primitive stage, however, these is some evidence to suggest an association of MetS with adiponectin levels, hematological indices, methylenetetrahydrofolate reductase (MTHFR) and Alpha-1A adrenergic receptor (ADRA1A) gene. These areas hold promise, and targeting these with appropriate interventions may help us to prevent the occurrence of MetS in patients with schizophrenia in future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.